HIMS HERS HEALTH INC

NYSE: HIMS (Hims & Hers Health, Inc.)

Last update: 15 Apr, 10:04PM

29.46

1.15 (4.06%)

  • 1D 4.06%
  • 5D 8.19%
  • 1M -0.30%
  • 6M 54.73%
  • YTD 16.90%
  • 1Y 135.12%
  • 5Y 195.49%
Previous Close 28.31
Open 28.49
Volume 14,475,760
Avg. Volume (3M) 24,907,281
Market Cap 6,545,010,176
Price / Earnings (TTM) 55.58
Price / Earnings (Forward) 47.17
Price / Sales 4.51
Price / Book 13.09
52 Weeks Range
11.20 (-61%) — 72.98 (147%)
Earnings Date 5 May 2025
Profit Margin 8.54%
Operating Margin (TTM) 4.69%
Diluted EPS (TTM) 0.530
Quarterly Revenue Growth (YOY) 95.10%
Quarterly Earnings Growth (YOY) 1,990.40%
Total Debt/Equity (MRQ) 2.38%
Current Ratio (MRQ) 1.79
Operating Cash Flow (TTM) 251.08 M
Levered Free Cash Flow (TTM) 178.69 M
Return on Assets (TTM) 7.18%
Return on Equity (TTM) 30.71%

Market Trend

Short Term Medium Term
Industry Household & Personal Products (US) Bearish Bearish
Household & Personal Products (Global) Bearish Bearish
Stock Hims & Hers Health, Inc. Bearish Bullish

AIStockmoo Score

-0.8
Analyst Consensus -0.5
Insider Activity -5.0
Price Volatility 2.0
Technical Moving Averages 0.0
Technical Oscillators -0.5
Average -0.80

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
HIMS 7 B - 55.58 13.09
ELF 4 B - 43.59 4.46
PG 378 B 2.50% 25.56 7.33
UL 157 B 2.94% 24.65 6.95
CL 77 B 2.09% 27.21 367.28
KMB 44 B 3.73% 17.95 39.45

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Sector Consumer Defensive
Industry Household & Personal Products
Investment Style Small Growth
% Held by Insiders 11.30%
% Held by Institutions 79.74%

Ownership

Name Date Shares Held
Iconiq Capital, Llc 31 Dec 2024 2,874,769
52 Weeks Range
11.20 (-61%) — 72.98 (147%)
Price Target Range
25.00 (-15%) — 68.00 (130%)
High 68.00 (Canaccord Genuity, 130.82%) Buy
Median 35.00 (18.81%)
Low 25.00 (Citigroup, -15.14%) Sell
Average 39.78 (35.03%)
Total 2 Buy, 5 Hold, 2 Sell
Avg. Price @ Call 36.39
Firm Date Target Price Call Price @ Call
B of A Securities 29 Apr 2025 26.00 (-11.74%) Sell 28.09
18 Mar 2025 22.00 (-25.32%) Sell 31.49
Morgan Stanley 29 Apr 2025 40.00 (35.78%) Hold 28.09
18 Feb 2025 60.00 (103.67%) Hold 58.50
TD Cowen 29 Apr 2025 30.00 (1.83%) Hold 28.09
Citigroup 25 Apr 2025 25.00 (-15.14%) Sell 28.09
06 Mar 2025 27.00 (-8.35%) Sell 34.39
Truist Securities 10 Apr 2025 33.00 (12.02%) Hold 26.81
26 Feb 2025 39.00 (32.38%) Hold 41.89
Leerink Partners 25 Feb 2025 40.00 (35.78%) Hold 39.86
Needham 25 Feb 2025 61.00 (107.06%) Buy 39.86
Piper Sandler 25 Feb 2025 35.00 (18.81%) Hold 39.86
Canaccord Genuity 19 Feb 2025 68.00 (130.82%) Buy 68.74
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BAIRD MELISSA - 25.84 -33,333 -861,325
BECKLUND IRENE - 25.35 -2,936 -74,428
DUDUM ANDREW - 26.95 -83,994 -2,263,638
Aggregate Net Quantity -120,263
Aggregate Net Value ($) -3,199,391
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 26.27
Name Holder Date Type Quantity Price Value ($)
BECKLUND IRENE Officer 22 Apr 2025 Automatic sell (-) 2,936 25.35 74,428
BAIRD MELISSA Officer 21 Apr 2025 Automatic sell (-) 33,333 25.84 861,325
BAIRD MELISSA Officer 21 Apr 2025 Option execute 33,333 - -
DUDUM ANDREW Officer 16 Apr 2025 Automatic sell (-) 36,460 26.95 982,597
DUDUM ANDREW Officer 16 Apr 2025 Automatic sell (-) 47,534 26.95 1,281,041
DUDUM ANDREW Officer 16 Apr 2025 Option execute 33,668 - -
  • 3M
Date Type Details
29 Apr 2025 Announcement Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
29 Apr 2025 CNBC Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
25 Apr 2025 CNBC Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
14 Apr 2025 Announcement Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
11 Mar 2025 Announcement Define Ventures Appoints Carolyn Magill as Venture Partner
07 Mar 2025 Announcement DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
24 Feb 2025 Announcement Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
21 Feb 2025 Announcement Hims & Hers Acquires US-based Peptide Facility
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
21 Feb 2025 CNBC Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions
19 Feb 2025 Announcement Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
04 Feb 2025 Announcement Hims & Hers Launches Health Collective and Community Member Council
03 Feb 2025 Announcement Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria